20 results about "Cellular immunity" patented technology

The application provides a cell fixing solution for a myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) and a product and application thereof, and relates to the technical field of in-vitro detection. The cell fixing solution provided by the application is composed of polyoxymethylene, formaldehyde, acetic acid, raffinose and a buffer solution, can effectively fix the cell morphology, maximally retains the natural spatial conformation and antigen epitope integrity of myasthenia gravis related antigens AChR, Titin, RyR1, MuSK and LRP4, reduces the problems of antigen denaturation, epitope shielding and protein loss in the fixing process, can efficiently and accurately realize the synchronous joint detection of various specific antibodies, and the myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) prepared by the application has stable detection results, and has important clinical application value and industrial popularization prospect.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

A method for treating a tumor, characterized by administering to an individual having a tumor immune effector cells expressing a receptor recognizing a tumor antigen and gemcitabine. A kit for treating a tumor, characterized by comprising: 1) immune effector cells expressing a receptor recognizing a tumor antigen; 2) gemcitabine; 3) a container for containing the above 1) and 2); and 4) a written notice for treating a tumor using the kit.

The present application relates to the technical fields of biological medicine and cellular immunotherapy, and particularly relates to a signal conversion receptor targeting IL-10, an engineered macrophage and application thereof. The signal conversion receptor is composed of an extracellular domain and a transmembrane domain and an intracellular domain derived from TLR9, and the extracellular domain sequentially comprises a signal peptide, a HA tag and a specific binding domain of an IL-10 receptor alpha subunit from N-terminal to C-terminal. The present application further prepares an engineered macrophage SR CAR-M capable of specifically recognizing IL-10 and converting it into a TLR9 activation signal, which can induce macrophages to polarize to M1 type and has excellent phagocytosis and killing capacity for bladder cancer, breast cancer, lung cancer and melanoma cells, and can be used for preparing related tumor treatment drugs, overcoming the common problems of existing cell therapy, such as easy exhaustion, difficult infiltration and easy inhibition in solid tumors, and having significant clinical transformation potential.

This invention belongs to the field of biodetection technology, specifically relating to a material for detecting anti-Caspr1 antibodies and its preparation method. The invention constructs an expression plasmid capable of highly expressing the Caspr1 antigen, transfects it into HEK293T cells, and modifies the original antigen sequence during construction to achieve normal membrane expression. Subsequently, a modified cell culture protocol is used to obtain a material for detecting anti-Caspr1 antibodies based on cellular immunofluorescence assay. This invention, based on cellular immunofluorescence, avoids the limitations of flow cytometry, which is complex and requires expensive equipment. By modifying the protein expression mode to normal membrane expression, it avoids cell permeabilization, avoids false negatives caused by antigen conformational changes in enzyme-linked immunosorbent assay (ELISA) and Western blotting, and avoids false negatives caused by transmembrane expression due to transfection with the original Caspr1 sequence.

The present application belongs to the technical field of cellular immunization engineering, and particularly relates to a polypeptide specifically recognizing PSCA and application thereof. The polypeptide provided by the present application specifically recognizes PSCA and has good affinity performance. The polypeptide specifically targeting PSCA provided by the present application can mark PSCA positive cells, combine with PSCA antigen and PSCA positive cells, and can be used as a detection reagent for PSCA molecules and an in-vivo tracing labeling reagent. The polypeptide specifically targeting PSCA provided by the present application can also be used in an extracellular antigen recognition region of a chimeric antigen receptor, and can be used in an immune cell treatment drug targeting PSCA to kill malignant tumors expressing PSCA. The polypeptide specifically recognizing PSCA of the present application is derived from a natural full human antibody, and compared with a mouse-derived antibody, a chimeric antibody and a humanized antibody, the immunogenicity is greatly reduced, and the safety can be maximally ensured in clinical application.

This invention belongs to the field of biodetection technology, specifically relating to a material for detecting anti-NF155 antibodies and its preparation method. This invention constructs an expression plasmid capable of highly expressing the NF155 antigen, transfects it into HEK293T cells, and modifies the pCDH vector with enhancers during construction. Subsequently, a modified cell culture protocol is used to obtain a material for detecting anti-NF155 antibodies based on a cell immunofluorescence methodology. This invention uses a cell immunofluorescence methodology to maximize the preservation of the antigen's spatial conformation through cell expression and antigen immobilization, preventing false negatives due to changes in binding sites. This invention selects the lentiviral vector pCDH to avoid the problem of non-specific binding that is difficult to distinguish, as the proteins expressed by common target gene vectors such as pcDNA3.1 may themselves contain antibody binding sites. This improves detection specificity and solves the problem of false negatives.

This invention discloses a porcine CD40L trimer protein, a recombinant Bacillus subtilis strain expressing this protein, and its applications, belonging to the fields of microbial genetic engineering and livestock and poultry biological products technology. This invention utilizes Bacillus subtilis WB800N as a host and pHT43 as a vector to successfully construct a recombinant strain that efficiently secretes and expresses porcine CD40L trimer protein. Soluble expression of the porcine CD40L trimer protein was achieved. The amino acid sequence of the porcine CD40L trimer protein expressed by the recombinant strain is shown in SEQ ID NO:1. Immunological activity verification using this porcine CD40L trimer protein revealed that the CD40L trimer protein expressed in this invention can simultaneously activate humoral and cellular immunity, possessing practical application value as a novel vaccine adjuvant.

The present application relates to a kind of nucleotide, vaccine comprising it and composite vaccine adjuvant.The sequence of the nucleotide is shown as SEQ ID No:1.Relative to conventional technology, the beneficial effects of the present application include: the present application adopts new optimized sequence, provides a kind of nucleotide, the nucleotide can be as CpG oligonucleotide adjuvant, induces vaccine antigen to produce stronger humoral immunity, cellular immunity level and anti-tumor immune effect etc., has obvious clinical application value and vaccine development value.Moreover, using the immunoadjuvant of the present application helps to reduce the dose of clinical use vaccine, improves safety.

The present application relates to the technical field of cellular immunotherapy, and particularly relates to a kind of targeting PSMA chimeric antigen receptor immune cells and preparation method and application thereof.A kind of targeting PSMA chimeric antigen receptor modified immune effector cell, the chimeric antigen receptor includes antigen binding domain, hinge region, transmembrane domain and signal transduction domain, and the antigen binding domain is anti-PSMA single-chain antibody.The chimeric antigen receptor modified immune effector cell provided in the present application can specifically recognize and combine the antigen binding domain of PSMA, and the prepared chimeric antigen receptor macrophage has specific killing effect on the target cells positive for PSMA protein, and can be used for preparing tumor drugs for treating or preventing PSMA positive.

The present application relates to the technical field of vaccine preparation, and particularly relates to a tetravalent dengue mRNA vaccine, a liposome nanoparticle and a preparation method and application thereof. The present application provides an mRNA vaccine (mRNA-LNP) encoding a liposome nanoparticle-wrapped EDIII structural protein of four kinds of serum types DENV in series and a polypeptide containing multiple TBT epitopes. After mice are inoculated with the vaccine, specific humoral immunity, cellular immunity with high levels against four kinds of serum types dengue virus are generated, and antibodies with neutralizing effects are also generated. The serum after immunization can protect 3-day-old suckling mice from lethal DENV attack, which indicates that the neutralizing antibodies generated by the vaccine are sufficient to resist the lethal challenge, and the vaccine is an effective vaccine which can be used for long-term research.

The present application belongs to the technical field of genetic engineering, and particularly relates to a recombinant plant lactobacillus for preventing and controlling chicken necrotic enteritis as well as a preparation method and application thereof. The present application provides an oral vaccine carrier capable of co-expressing multiple key virulence factor antigens (FimB, NetB, CnaA, FBA) of Clostridium perfringens, and the efficiency of the vaccine carrier being recognized and taken by professional antigen presenting cells is significantly improved through fusion of dendritic cell (DC) targeting molecules (nanobody Phi74), so as to enhance immunogenicity. Immunization of animals using the recombinant lactobacillus can induce mucosal immunity, cellular immunity and humoral immunity response, and comprehensively enhance the immune ability of the body, thereby establishing a safe, efficient and suitable oral immunization scheme for large-scale breeding for treating chicken necrotic enteritis.

The application belongs to the field of nuclear medicine and relates to a T cell immunoglobulin and mucin domain-3 targeted compound and application. 68 Ga labeled TIM-3 targeted molecular probes can realize imaging of TIM-3 positive tumors and exhibit good potential as TIM-3 targeted PET imaging agents.

The application provides a cell climbing sheet processing reagent for a Ranvier node / paranode antibody spectrum detection kit (cellular immunofluorescence method), a method and application thereof, and relates to the technical field of in-vitro detection. The cell climbing sheet processing reagent comprises a cell fixing solution with a specific composition and an antigen repair composition after cell fixing, wherein the cell fixing solution is composed of paraformaldehyde, formaldehyde, acetic acid, raffinose and a buffer solution, and the antigen repair composition after cell fixing is composed of ammonium sulfate, hydroxylamine hydrochloride, Brij 78, TCEP, ProClin 300 and a buffer solution. Through the synergistic effect of the two, the natural conformation of the target antigen is maximally retained, and non-specific interference is reduced, so that precise and efficient detection of the Ranvier node / paranode antibody spectrum NF155, NF186, CNTN1, CASPR1 and MAG can be realized, the clinical diagnosis demand is met, and reliable technical support is provided for precise typing of autoimmune Ranvier node disease.

This invention discloses a triple inactivated vaccine against porcine circovirus type 2 (PCV2), Mycoplasma hyopneumoniae, and Streptococcus suis, and its preparation method, belonging to the field of veterinary biological products technology. The invention consists of an antigen and a vaccine adjuvant; the antigen is composed of PCV2 antigen, Mycoplasma hyopneumoniae antigen, and Streptococcus suis antigen; the PCV2 antigen is the PCV-2 d-cap protein obtained through genetic engineering; the Mycoplasma hyopneumoniae antigen is inactivated Mycoplasma hyopneumoniae (ES-2) bacterial suspension; the Streptococcus suis is inactivated SS2 and SS9 type Streptococcus suis bacterial suspension; the adjuvant is a novel aqueous adjuvant capable of enhancing cellular and humoral immunity. The triple inactivated vaccine against PCV2, Mycoplasma hyopneumoniae, and Streptococcus suis provided by this invention exhibits significant advantages in preventing these three swine diseases.

The invention discloses application of a taste sense 2 receptor member 31 (TAS2R31) as a knockout target in cellular immunotherapy, and belongs to the technical field of biological medicines. Specifically, it is found for the first time that the proliferation capacity of tumor infiltrating lymphocytes (TIL cells) obtained after TAS2R31 gene is knocked out is remarkably improved, the killing capacity is remarkably enhanced, and the cell phenotype can be converted towards the direction more beneficial to anti-tumor immunity; meanwhile, the TIL cells with the TAS2R31 gene knocked out can release functional cell factors after being stimulated by antigens, and the TIL cells have definite anti-tumor immunocompetence. Therefore, the TAS2R31 is used as a new knockout target and is used for developing a new tumor treatment scheme based on TIL cells or TCR-T cells. The cell therapy provided by the invention provides a new strategy direction for tumor treatment by improving the multiplication capacity and the immune function of the TIL cells and the TCR-T cells.

A vaccine for Mycobacterium tuberculosis, in particular, the vaccine comprises an immunological composition comprising an antigen component and a granulin component. The granulin component comprises a nanoparticle protein, and the antigen component is covalently bound to the granulin component through binding peptide 1 and binding peptide 2 to form an immunogenic complex. The vaccine shows excellent cellular immunogenicity and antibody immunogenicity. The preparation method of the vaccine is also involved.

This invention discloses an injectable composite hydrogel adjuvant, its preparation method, and its application. The composite hydrogel adjuvant is formed by conjugating the TLR receptor 7 agonist Gardimquid to chitosan oligosaccharide, and then adding the Gardimquid-conjugated chitosan oligosaccharide to an oxidized hyaluronic acid solution, forming a stable gel through chemical cross-linking. This composite hydrogel adjuvant is loaded with calcium phosphate-mineralized type O foot-and-mouth disease virus-like particles to form a hydrogel vaccine. Experimental results show that the vaccine has excellent biocompatibility, recruiting 16.12% dendritic cells and 9.62% macrophages (antigen-presenting cells), and has the ability to enhance antigen migration and uptake, and promote immune cell activation. Furthermore, it can induce sustained and potent levels of specific antibodies and cellular immunity, and maintain immune memory for 20 weeks. This invention provides an effective technical means to improve the duration of immunity from foot-and-mouth disease virus-like particles, enhance the immunization effect, and achieve single-dose immunization.

The application discloses a plant-based functional protein composition with immunoregulation and application thereof, and belongs to the technical field of functional food. The composition takes plant-derived proteins and protein peptides as cores, and contains peanut peptides 40-60%, seaweed proteins 5-10%, and soybean peptides 1-5% in terms of mass percentage. Optionally, the composition can further contain pea proteins 1-3%, quinoa proteins 0.1-2%, and 3-20% of food-grade auxiliary materials. The application can significantly regulate the immune activity of macrophages by scientifically compounding various plant-derived active ingredients, and the synergistic effect of the components. The composition has wide raw material sources, high safety, and balanced nutrition, and can be widely applied to the preparation of immunoregulation food or health food, and is suitable for various people who need to enhance immunity, so that the application has wide market application prospects.